Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
An RX mirror and its underlying label are not independent clinical confirmations.
Check source scope before reading a dose
AUGTYRO: selected primary-label renal guidance and limits
Product / population
AUGTYRO oral capsules for the labeled molecularly selected oncology indication and age group; not a full oncology regimen.
Renal method
eGFR, mL/min as printed in section 8.6
Source revision
Revision date not captured in selected review; retrieval date is not revision date.
Retrieved
2026-11-07
Local review status
Selected sections checked against the identified source; not a complete monograph or independent clinician approval.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
AUGTYRO: source applicability and renal evidence limits
Section 8.6 prints eGFR 30-90; supporting PK wording uses 30 to <90. The dosing summary explicitly follows section 8.6. This is not evidence for a new dialysis recommendation.
What to reconcile: Use the full indication, interactions and toxicity-modification instructions.
DailyMed / product prescribing information · AUGTYRO oral capsules for the labeled molecularly selected oncology indication and age group; not a full oncology regimen.
Renal method: eGFR, mL/min as printed in section 8.6 Source date: Revision date not captured in selected review; retrieval date is not revision date. Retrieved: 2026-11-07
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding
eGFR <30 or dialysis: recommended dose not established.
Dialysis evidence: No dialysis regimen established in selected content
Selected sections checked against the identified source; not a complete monograph or independent clinician approval.
Section 8.6 and supporting 12.3
No dose modification is recommended for mild/moderate impairment (eGFR 30-90 mL/min as stated in section 8.6). The recommended dose is not established with eGFR <30 or on dialysis. The supporting PK paragraph uses 30 to <90; this minor boundary-wording difference is retained in provenance rather than silently rewriting the renal-use section.
RDM72-repotrectinib-augtyro-label-1 · Source locator: Section 8.6 and supporting 12.3
Source-specific limits
Selected renal section, not a complete prescribing monograph. A label and its mirror are not independent evidence.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.
